about
Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in ratsAntidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor.Synthesis and activity of newly designed aroxyalkyl or aroxyethoxyethyl derivatives of piperazine on the cardiovascular and the central nervous systems.Design, synthesis, and biological evaluation of fluorinated imidazo[1,2-a]pyridine derivatives with potential antipsychotic activity.Molecular mechanism of action and safety of 5-(3-chlorophenyl)-4-hexyl-2,4-dihydro-3H-1,2,4-triazole-3-thione - a novel anticonvulsant drug candidate.Chemically Homogenous Compounds with Antagonistic Properties at All α1-Adrenoceptor Subtypes but not β1-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in RatsSynthesis and adrenolytic activity of new propanolamines.Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test.Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H3 receptor ligands.Biofunctional studies of new 2-methoxyphenylpiperazine xanthone derivatives with α₁-adrenolytic properties.Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action.The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT(1A) and 5-HT(2A/C) receptors activation.Mechanisms of morphine-venlafaxine interactions in diabetic neuropathic pain model.Prolonged administration of antidepressant drugs leads to increased binding of [(3)H]MPEP to mGlu5 receptors.Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT7 receptor agents with antidepressant activity.5-HT1A and 5-HT2A receptors affinity, docking studies and pharmacological evaluation of a series of 8-acetyl-7-hydroxy-4-methylcoumarin derivatives.Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Chronic antidepressant-like effect of EMD386088, a partial 5-HT receptor agonist, in olfactory bulbectomy model may be connected with BDNF and/or CREB signalling pathwayStudies on Anticonvulsant Effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in RatsHBK-17, a 5-HT Receptor Ligand With Anxiolytic-Like Activity, Preferentially Activates ß-Arrestin Signaling4-tert-Pentylphenoxyalkyl derivatives - Histamine H receptor ligands and monoamine oxidase B inhibitorsSynthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α/α-Adrenergic Receptor Antagonist with Potential Uroselective ProfileNew Dual Small Molecules for Alzheimer's Disease Therapy Combining Histamine H3 Receptor (H3R) Antagonism and Calcium Channels Blockade with Additional Cholinesterase InhibitionAnalysis of Density Changes of Selected Brain Receptors After a 14-Day Supply of Chromium(III) and Evaluation of Chromium(III) Affinity to Selected Receptors and TransportersThe Possibilities of Using Chromium Salts as an Agent Supporting Treatment of Polycystic Ovary SyndromeOptimization and preclinical evaluation of novel histamine H3receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivativesSynthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands
P50
Q28275114-CC55AD16-6930-4B69-970B-ABE4C796793EQ34488146-122B54EC-A04B-4648-A963-45750D732A2FQ38737646-5B72ACFD-9330-42C4-B717-0047499E2337Q38824061-1D99ADD9-63EE-49AC-BDAF-0F6A77ED5CF7Q41454841-2C5DD8C9-686A-4E5A-80B0-711DED6C71BDQ42058859-9B45DFCF-E9C3-4A8B-9C0A-862596271B1EQ42958817-C1A4C219-BE1F-4FF3-8954-6A49EFEB5C94Q44705916-400AF506-5F96-4093-9B9D-9E053DA771AAQ46336024-0BF829A8-11EB-4705-9A1E-F89E46CEB9BFQ46526511-92E6BE04-EF59-457B-95B4-21EB85DDFBA1Q47305379-4E123844-2D34-4699-8BB4-AB44F8788262Q48069023-48AC09C5-68DF-448D-A8EF-F5CD5676FBB7Q48077440-A72BD2AB-85C7-4A20-9767-394EECF9D740Q48390557-491A1E90-F857-4F9C-94B8-C611C529F6A0Q48793956-82EB14FA-1FB8-4FAB-B553-E075AD63B1A1Q50096564-00A4C3BF-85F0-45C4-B2A5-DB656889FB46Q50134838-BA37B764-1B45-42A3-974A-1242F643969CQ50664660-860A449B-D182-4785-9C0D-28B49D50758DQ57193082-9841DD2B-5177-4CFC-8BB4-78D93FEF827FQ58103536-8373E098-A5D5-420D-8BCB-B3CAC9E6DA8DQ58554121-4552C147-10D7-4FAC-9408-EC068049D16FQ58582275-5DF26139-DE53-480B-8B06-D7A89BC148D3Q58691700-A0A9C770-8FCE-40BC-82CD-46640B0D2143Q91277453-C9AD9E69-3751-4981-986B-8A8714D8476DQ91303767-4453AAC7-EBC0-40E8-A7A1-3A3ADBC86D00Q91330830-140CD446-D62C-4925-A794-43D8A097F855Q93193139-A43F7F4E-41B9-47D1-915C-9D4B1217A1FAQ95529366-1D6E7996-B76D-415C-B354-FAE25AEED934
P50
description
researcher (ORCID 0000-0001-5321-9266)
@en
name
Agata Siwek
@en
type
label
Agata Siwek
@en
prefLabel
Agata Siwek
@en
P31
P496
0000-0001-5321-9266